Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
63.70    -2.50 (-3.78%)
Bid:
63.40
Ask:
63.70
Spread: 0.30 (0.473%)
Market Cap: £562.74m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Share buyback programme update

26 Jun 2025 16:19

RNS Number : 6278O
IP Group PLC
26 June 2025
 

FOR RELEASE ON

26 June 2025

 

 

IP Group plc - Share buyback programme update

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to provide the following update.

In line with its previously announced intention, the Group is now allocating all of the proceeds it has received to date from the secondary sale announced on 09 December 2024 together with 50% of the Group's other realisations received in 2025, being £20m in aggregate, towards its buyback programme (the "Buyback Programme"). The Buyback Programme will therefore today be extended by £20m to a total of £75m (the "Buyback Extension").

The Buyback Extension will run until 31 December 2025 unless completed or terminated earlier, or unless the Company and Deutsche Numis agree otherwise (in which event an announcement would be made).

Since commencing the Buyback Programme, the Group has purchased 122,904,597 shares at an average price of 44.8 pence per share for an aggregate consideration of £55m. All shares acquired under the Buyback Programme have been, or will shortly be, cancelled. Following such cancellation, the Company's issued share capital consists of 918,491,679 Ordinary Shares with voting rights and there are no Ordinary Shares held in treasury.

Details of the Buyback Extension

 

For the Buyback Extension, IP Group has entered into a non-discretionary agreement with Deutsche Numis to continue to manage the Buyback Programme on its behalf. Deutsche Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group.

Any Ordinary Shares purchased under the Buyback Extension will be cancelled.

The Buyback Extension is in accordance with IP Group's general authority to purchase a maximum of 141,415,378 Ordinary Shares granted by its shareholders at the Annual General Meeting held on 12 June 2025. The Buyback Programme will continue to be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019), and in accordance with Chapter 9 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it is not in a closed period and currently has no other unpublished price sensitive information.

Save to the extent they are varied by this announcement, all other parameters outlined in the Company's announcement on 18 December 2023 will continue to apply.

IP Group will continue to make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Alex Donaldson

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutionsOur specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPKABDPBKDFAB
Date   Source Headline
26th Jun 202312:41 pmRNSDirector Declaration
15th Jun 20231:19 pmRNSResult of AGM
15th Jun 20237:00 amRNSAGM Statement
8th Jun 20238:51 amRNSLife Sciences update event
7th Jun 202311:00 amRNSIP Group plc - TR1 form
31st May 20232:34 pmRNSTotal Voting Rights
12th May 20231:26 pmRNSDirector Declaration
10th May 202312:11 pmRNSDirector/PDMR Shareholding
3rd May 202310:56 amRNSDirector Declaration
28th Apr 20233:21 pmRNSTotal Voting Rights
20th Apr 20235:00 pmRNSNotice of AGM, Annual Report
18th Apr 20233:23 pmRNSRSP & DBSP awards; Director/PDMR shareholding
15th Mar 20239:31 amRNSInvestor presentation
13th Mar 20239:00 amRNSDirector/PDMR Shareholding
13th Mar 20237:00 amRNSNo direct deposits or credit facilities with SVB
8th Mar 20237:00 amRNSIP Group plc - Annual Results
2nd Mar 20233:25 pmRNSTR-1
21st Feb 20237:00 amRNSAMSL Aero's all-electric aircraft maiden flight
10th Feb 20239:55 amRNSNotice of Results
31st Jan 202310:00 amRNSTotal Voting Rights
30th Jan 20237:00 amRNSStatement re press speculation
24th Jan 20231:18 pmRNSForm 8.3 - Mirriad Advertising plc
18th Jan 20237:00 amRNSDirectorate Change
11th Jan 20237:00 amRNSPortfolio company Oxbotica raises $140m Series C
3rd Jan 202311:48 amRNSTotal Voting Rights
12th Dec 20224:58 pmRNSAGM post-meeting shareholder engagement update
7th Dec 20224:39 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIstesso announces FDA Fast Track for MBS2320
2nd Dec 202211:38 amRNSPortfolio company funding leads to £36m gain
30th Nov 202210:41 amRNSTotal Voting Rights
21st Nov 20222:13 pmRNSLife sciences presentation postponed
2nd Nov 20223:51 pmRNSInvestor presentation on life sciences
1st Nov 20228:59 amRNSNotification of major holdings
31st Oct 20224:35 pmRNSDirector/PDMR Shareholding
27th Oct 20224:55 pmRNSPDMR Dealing – SAYE Exercise
24th Oct 20226:02 pmRNSHolding(s) in Company
14th Oct 20229:42 amRNSHolding(s) in Company
30th Sep 202210:39 amRNSTotal Voting Rights
21st Sep 20225:29 pmRNSHolding(s) in Company
20th Sep 20226:10 pmRNSDirector/PDMR Shareholding
15th Sep 20224:41 pmRNSInvestor presentation
14th Sep 20224:33 pmRNSFurther re Scrip Dividend
13th Sep 20226:00 pmRNSFurther re Interim Scrip Dividend
13th Sep 20227:01 amEQSIP Group Trust (IPO): Initiation — International investor in impactful innovation
7th Sep 20224:33 pmRNSDirector/PDMR Shareholding, SAYE scheme
31st Aug 20228:51 amRNSIstesso starts Phase 2b trial of MBS2320
30th Aug 202212:59 pmRNSCash acquisition of portfolio company Diurnal
18th Aug 20229:25 amRNSScrip Dividend Reference Price
11th Aug 202210:50 amRNSHolding(s) in Company
3rd Aug 20227:00 amRNSHalf-yearly results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.